Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: The SHORE study

Keyphrases

• Retinal Vein Occlusion 100%
• Ranibizumab Injection 100%
• Pro Re Nata 100%
• Best-corrected Visual Acuity 62%
• No Significant Difference 25%
• Mean Standard Deviation 25%
• Change from Baseline 25%
• Ranibizumab 25%
• Central Subfield Thickness 25%
• Stability Criteria 25%
• Macular Edema 12%
• Examiner 12%
• Visual Outcome 12%
• Branch Retinal Vein Occlusion 12%
• Visual Gain 12%
• Early Treatment Diabetic Retinopathy Study 12%
• Difference in Mean 12%
• Thickness Reduction 12%
• Edema Resolution 12%

Medicine and Dentistry

• Best Corrected Visual Acuity 100%
• Ranibizumab 100%
• Retina Vein Occlusion 100%
• Central Retinal Vein Occlusion 20%
• Macular Edema 20%
• Edema 20%
• Diabetic Retinopathy 20%
• Branch Retinal Vein Occlusion 20%

Neuroscience

• Ranibizumab 100%
• Retinal Vein Occlusion 100%
• Diabetic Retinopathy 25%
• Central Retinal Vein 25%